Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Director | June 17, 2025 | June 18, 2025 |
| Duke Energy CORPDUK · Entity 2925 | Director | May 07, 2026 | May 11, 2026 |
| ILLUMINA, INC.ILMN · Entity 3137 | Director | May 20, 2026 | May 22, 2026 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director | June 14, 2022 | June 16, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date June 17, 2025 · Filed June 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,002 |
Reported balance
After 2025-06-17 transaction · row 1
1 source rowRow 1 · 2025-06-17 · Grant · Acquired 3,160 · Balance 31,002 |
Duke Energy CORP
Report date May 07, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,723 |
Reported balance
After 2026-05-07 transaction · row 1
1 source rowRow 1 · 2026-05-07 · Grant · Acquired 1,602 · Balance 12,723 |
ILLUMINA, INC.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,754 |
Ending reported balance
After 2026-05-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-20 · Tax withholding · Disposed 1,512 · Balance 13,682 Row 2 · 2026-05-21 · Grant · Acquired 2,072 · Balance 15,754 F1: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date.
Intellia Therapeutics, Inc.
Report date June 14, 2022 · Filed June 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,701 |
Reported balance
After 2022-06-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-06-14 · Grant · Acquired 5,197 · Balance 12,701 F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.49 · Expires 2032-06-13 | Direct | 7,688 |
Reported balance
After 2022-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-14 · Grant · Acquired 7,688 · Balance 7,688 F2: This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2: This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
Past disclosures · reporting ended (8)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GILEAD SCIENCES, INC.
Report date January 21, 2008 · Filed January 29, 2008
Section 16 reporting ended · disclosed 2008-01-29. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
GOLDMAN SACHS MLP & ENERGY RENAISSANCE FUND
Report date February 10, 2021 · Filed February 12, 2021
Section 16 reporting ended · disclosed 2021-02-12. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Goldman Sachs Credit Income Fund
Report date February 10, 2021 · Filed February 12, 2021
Section 16 reporting ended · disclosed 2021-02-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Shares of Beneficial InterestSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2021-02-10 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Goldman Sachs MLP Income Opportunities Fund
Report date September 28, 2020 · Filed September 30, 2020
Section 16 reporting ended · disclosed 2020-09-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Shares of Beneficial InterestSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2020-09-28 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Goldman Sachs Private Markets Fund 2018 (A) LLC
Report date November 08, 2018 · Filed November 27, 2018
Section 16 reporting ended · disclosed 2018-11-27. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Goldman Sachs Private Markets Fund 2018 (B) LLC
Report date November 08, 2018 · Filed November 27, 2018
Section 16 reporting ended · disclosed 2018-11-27. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Goldman Sachs Private Markets Fund 2018 LLC
Report date November 08, 2018 · Filed November 27, 2018
Section 16 reporting ended · disclosed 2018-11-27. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Goldman Sachs Real Estate Diversified Income Fund
Report date February 10, 2021 · Filed February 12, 2021
Section 16 reporting ended · disclosed 2021-02-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Shares of Beneficial InterestSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2021-02-10 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 22, 2026 21:08 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 2,072 | $144.83 | $300,087.76 |
DisclosureSEC source: 0001110803-26-000114 · form4.xml · nonDerivative · entry 2 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,754 F1 · shares: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| May 20, 2026 Filed May 22, 2026 21:08 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 1,512 | $141.92 | $214,583.04 |
DisclosureSEC source: 0001110803-26-000114 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,682 Read SEC document |
| May 07, 2026 Filed May 11, 2026 20:26 UTC | Duke Energy CORP DUK · Entity 2925 | GrantCommon Stock | 1,602 | $124.87 | $200,041.74 |
DisclosureSEC source: 0001181174-26-000002 · wk-form4_1778531178.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,723 Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:34 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 3,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-017756 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,002 Read SEC document |
| May 21, 2025 Filed May 23, 2025 21:09 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 3,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-015514 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,194 F1 · shares: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| May 16, 2025 Filed May 20, 2025 20:19 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 1,070 | $83.62 | $89,473.40 |
DisclosureSEC source: 0001127602-25-015017 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,414 F1 · balance_after: In connection with Illumina's spin out of Grail, Inc., which was completed on June 24, 2024, all unvested equity award units were adjusted pursuant to Illumina's Amended and Restated 2015 Stock and Incentive Plan. Ms. Dorsa's unvested RSUs were increased by 53 units as a result of such adjustment. Read SEC document |
| May 02, 2025 Filed May 5, 2025 20:17 UTC | BIOGEN INC. BIIB · Entity 1675 | PurchaseCommon Stock | 1,235 | $122.72 | $151,559.20 |
DisclosureSEC source: 0001127602-25-013345 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,842 Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:36 UTC | Duke Energy CORP DUK · Entity 2925 | GrantCommon Stock | 1,607 | $121.33 | $194,977.31 |
DisclosureSEC source: 0001326160-25-000134 · wk-form4_1746477360.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,121 Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 21:06 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-019231 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,607 Read SEC document |
| May 16, 2024 Filed May 17, 2024 22:23 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 2,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-015934 · form4.xml · nonDerivative · entry 2 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,431 F1 · shares: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| May 15, 2024 Filed May 17, 2024 22:23 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 612 | $115.01 | $70,386.12 |
DisclosureSEC source: 0001127602-24-015934 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,809 Read SEC document |
| May 09, 2024 Filed May 13, 2024 20:20 UTC | Duke Energy CORP DUK · Entity 2925 | GrantCommon Stock | 1,698.699 | $103.02 | $174,999.97 |
DisclosureSEC source: 0001326160-24-000134 · wk-form4_1715631610.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,514 F1 · shares: Any fraction of a share is paid out in cash upon distribution. Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 22:59 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019541 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,822 Read SEC document |
| May 26, 2023 Filed May 31, 2023 20:55 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 1,532 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-017235 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,421 F1 · shares: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| May 24, 2023 Filed May 25, 2023 20:33 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 492 | $212.65 | $104,623.80 |
DisclosureSEC source: 0001127602-23-016870 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,889 Read SEC document |
| May 04, 2023 Filed May 8, 2023 20:57 UTC | Duke Energy CORP DUK · Entity 2925 | GrantCommon Stock | 1,783.712 | $98.11 | $174,999.98 |
DisclosureSEC source: 0001326160-23-000139 · wf-form4_168357941347893.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,816 F1 · shares: Any fraction of a share is paid out in cash upon distribution. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:31 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-017776 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,242 Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 22:26 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 7,688 | $0.00 Strike: $38.49 | $0.00 |
DisclosureSEC source: 0001209191-22-037595 · doc4.xml · derivative · entry 2 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,688 Underlying: Common Stock · 7,688 shares Expires 2032-06-13 F2 · derivative.exercise_date: This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 22:26 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 5,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037595 · doc4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,701 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| May 26, 2022 Filed May 27, 2022 23:28 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 1,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-015918 · form4.xml · nonDerivative · entry 2 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,381 F1 · shares: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| May 25, 2022 Filed May 27, 2022 23:28 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 352 | $242.40 | $85,324.80 |
DisclosureSEC source: 0001127602-22-015918 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,149 Read SEC document |
| May 05, 2022 Filed May 9, 2022 20:21 UTC | Duke Energy CORP DUK · Entity 2925 | GrantCommon Stock | 1,590 | $110.05 | $174,979.50 |
DisclosureSEC source: 0001326160-22-000205 · wf-form4_165212767737308.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,031 Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 21:34 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 775 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-021351 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,872 Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 22:03 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 3,382 | $0.00 Strike: $83.59 | $0.00 |
DisclosureSEC source: 0001209191-21-043372 · doc4.xml · derivative · entry 2 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,382 Underlying: Common Stock · 3,382 shares Expires 2031-06-22 F2 · derivative.exercise_date: This option was granted on June 23, 2021 with respect to 3,382 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 22:03 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 2,094 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043372 · doc4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,094 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:48 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,000 | $450.00 | $450,000.00 |
DisclosureSEC source: 0001127602-21-019825 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,501 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| May 26, 2021 Filed May 27, 2021 21:24 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 881 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-018200 · form4.xml · nonDerivative · entry 2 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,501 F1 · security: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| May 25, 2021 Filed May 27, 2021 21:24 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 385 | $397.09 | $152,879.65 |
DisclosureSEC source: 0001127602-21-018200 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,620 Read SEC document |
| May 06, 2021 Filed May 11, 2021 00:14 UTC | Duke Energy CORP DUK · Entity 2925 | GrantCommon Stock | 1,591.406 | $100.54 | $159,999.96 |
DisclosureSEC source: 0001326160-21-000162 · wf-form4_162069202977468.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,441.406 Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 22:09 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0001209191-21-025734 · doc4.xml · derivative · entry 5 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,088 Underlying: Common Stock · 7,500 shares Expires 2025-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 22, 2018. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 22:09 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 800 | $82.99 | $66,392.00 |
DisclosureSEC source: 0001209191-21-025734 · doc4.xml · nonDerivative · entry 4 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,410 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.875 to $83.13, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 5, 2021 at each separate price. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 22:09 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 4,686 | $82.35 | $385,892.10 |
DisclosureSEC source: 0001209191-21-025734 · doc4.xml · nonDerivative · entry 3 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,210 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.84 to $82.83, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 5, 2021 at each separate price. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 22:09 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,014 | $81.49 | $164,120.86 |
DisclosureSEC source: 0001209191-21-025734 · doc4.xml · nonDerivative · entry 2 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,896 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.835 to $81.81, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 5, 2021 at each separate price. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 22:09 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 7,500 | $6.40 | $48,000.00 |
DisclosureSEC source: 0001209191-21-025734 · doc4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 20:44 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $20.72 | $0.00 |
DisclosureSEC source: 0001209191-20-037961 · doc4.xml · derivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: This option was granted on June 18, 2020 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:13 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019019 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,097 Read SEC document |
| May 27, 2020 Filed May 28, 2020 21:59 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 963 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-018075 · form4.xml · nonDerivative · entry 2 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,005 F1 · security: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| May 26, 2020 Filed May 28, 2020 21:59 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 519 | $354.41 | $183,938.79 |
DisclosureSEC source: 0001127602-20-018075 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,042 Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 21:48 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022416 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,207 Read SEC document |
| May 29, 2019 Filed May 30, 2019 21:21 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 1,298 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-020248 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,561 F1 · security: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| May 23, 2019 Filed May 29, 2019 00:30 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 589 | $308.97 | $181,983.33 |
DisclosureSEC source: 0001127602-19-020061 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,263 Read SEC document |
| May 21, 2019 Filed May 22, 2019 20:33 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $15.78 | $0.00 |
DisclosureSEC source: 0001209191-19-032078 · doc4.xml · derivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2029-05-20 F1 · derivative.exercise_date: This option was granted on May 21, 2019 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 21:29 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 880 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-020954 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,052 Read SEC document |
| May 23, 2018 Filed May 24, 2018 23:15 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 1,473 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-018869 · form4.xml · nonDerivative · entry 2 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,852 F1 · security: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| May 22, 2018 Filed May 24, 2018 23:15 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 922 | $270.80 | $249,677.60 |
DisclosureSEC source: 0001127602-18-018869 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,379 Read SEC document |
| May 17, 2018 Filed May 21, 2018 16:54 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $25.98 | $0.00 |
DisclosureSEC source: 0001209191-18-031690 · doc4.xml · derivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2028-05-16 F1 · derivative.exercise_date: This option was granted on May 17, 2018 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| March 23, 2018 Filed Mar 26, 2018 21:12 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 410 | $24.05 | $9,860.50 |
DisclosureSEC source: 0001209191-18-021644 · doc4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,410 Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 21:57 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-021105 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,172 F1 · balance_after: On 6/8/16 an RSU was awarded for 1,060 shares. This award was adjusted to 1,084 shares pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 12:03 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 5,000 | $12.42 | $62,100.00 |
DisclosureSEC source: 0001209191-17-037520 · doc4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| May 30, 2017 Filed Jun 2, 2017 00:39 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 2,305 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-020130 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,301 F1 · security: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.